ystic fibrosis (CF) is a common autosomal recessive genetic disorder caused by a variety of sequence alterations in the CFTR gene. Since the cloning of the cystic fibrosis transmembrane regulator (CFTR) gene in 1989, more than 2000 mutations were reported to the Cystic Fibrosis Consortium database (http://www.genet.sickkids.on.ca).
Of more than 200 CFTR gene polymorphisms described so far, some are quite common and can be found in general population with frequencies up to 40% (Cuppens et al., 1993; Bombieri et al., 2000) . The molecular pathogenesis of polymorphisms in the CFTR gene is not understood, although recent studies have shown that some polymorphism exhibit many features of CFTR-related disorders (CFTR-RD), suggesting the important role of these polymorphisms in CFTR gene expression (Cuppens et al., 1998) .
The interactions between mutations and polymorphisms within CFTR, polymorphisms in other genes, and the environment leads not only to significant symptom variability in patients with classical CF, but possibly also to ''nonclassical'' CF (Boyle, 2003) and a growing number of monosymptomatic diseases such as obstructive azospermia, idiopathic pancreatitis, disseminated bronchiectasis, and chronic rhinosinusitis. The relative contributions of individual genetic factors and the environment to disease phenotype are currently unclear, but it is most likely that multiple CF modifier genes are involved (Davies et al., 2005) .
Single nucleotide polymorphisms (SNPs) are being intensively studied to understand the biological basis of complex traits and diseases. The genetics of human phenotype variation could be understood by knowing the functions of SNPs (George Priya Doss et al., 2008) . Genetic analyses indicated that functional polymorphisms in the CFTR gene can alter the expression of CFTR (Cuppens et al., 1998) but cannot cause CF without additional CFTR mutations (Davies et al., 2005) .
The
SNPs c.1540A>G, c.2694T>G, and c.4521G>A may have affected pre-mRNA splicing by changing regulatory sequence motifs of exonic splice enhancers, leading to lower amounts of normal transcripts (Steiner et C al., 2004) and could contribute to an increased risk in the development of chronic pancreatitis (De Cid et al., 2010) . Previous studies have suggested that the most frequent polymorphism in CFTR gene, the M470V in exon 10, which represents for A or G variation at position 470, plays a role in modulating CFTR protein at both transcriptional and translational levels. It was reported that the M470-CFTR was associated with a 1.7-fold of the V470 CFTR function (Cuppens et al., 1998) . Several CFTR variants indicated to be more frequent in certain clinical conditions than in healthy individuals. Three of them, 5T, M470V, and R75Q, have been shown to be relatively frequent in Serbian patients with monosymptomatic CF disorders (Nikolic et al., 2006) . Interestingly, the frequency of common CFTR polymorphism differ in different countries and populations, such as, the prevalence of V470 allele is strikingly low in Sub-Saharan Africans and in African-Americans, with a frequency approximately 1/5 of that in other populations (http://www.ncbi.nlm.nih.gov. gate1.inist.fr/SNP/snp_ref.cgirs= 213950).
Moreover, it has been reported that poly-T, TG-repeats and M470V polymorphisms play roles in the development of CF-like diseases (Noone et al., 2000; Huang et al., 2008) . The polythymidine variants in intron 8 [IVS8-poly (T)] are associated with the efficient usage of the intron 8 splicing acceptor site, and affect the transcription of exon 9 mRNA by exon skipping. The IVS8-5T results in approximately 90% of exon 9 skipping, leading to a nonfunctional CFTR, thereby is considered as a disease mutation with incomplete penetrance (Chu et al., 1993) .
In this study, the consequence of four frequent CFTR polymorphisms separately (c.1540A>G, c.2694T>G, c.4404C>T and c.4521G>A) or in allelic complexes in cis was analyzed in vitro to assess the pathogenesis of these polymorphisms on clinical phenotypes.
MATERIALS AND METHODS

Construction of a green fluorescent protein (GFP)-tagged mutated CFTR.
The GFP-tagged CFTR plasmids (wild-type (WT), and F508del-CFTR) were generously provided by B. Stanton (Dartmouth Medical School, Hanover, NH). Specific variant substitutions alone (c.1540A>G), (c.2694T>G), (c.4404C>T) and (c.4521G>A) or in different associations were introduced into the WT-CFTR plasmid using the Gene tailor site-directed mutagenesis kit (Invitrogen, Carlsbad, CA) using the designed primers and according to the manufacturer's protocol ( Fig. 1 and Table 1 ). The sequence of each plasmid containing the desired variants in individual clones was controlled through plasmid sequencing on both strands using the ABI PRISM Big Dye Terminator™ Cycle Sequencing Ready Reaction Kit (Applied Biosystems). Reactions were run on an ABI PRISM™ 310 automatic sequencer (Applied Biosystems).
Cell culture and transient transfection
Hela cells were grown in a DMEM medium with Glutamax-I (Life Technolo-gies) amended with 10% fetal bovine serum (FBS, Gibco) and 100 unit/ml penicillin, 100 µg/ml streptomycin in humidified incubator at 37C in the presence of 5% CO 2 . Wild-type and mutant CFTR were transiently expressed in HeLa cells using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions.
Examination of distribution of GFP-CFTR by confocal microscopy
Forty-eight hours after transfection, Hela cells were washed twice with icecold PBS and fixed in paraformaldehyde (3% in TBS) for 10 min at 4C. Nuclei were stained with TOPRO-3 iodide (1:1000 in TBS, Molecular Probes). Cover glasses containing cells were mounted in Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired using a reversed microscope (Olympus IX 70) equipped with a laser scanning confocal unit (model MRC-1024, BioRad), a 15 m W kryptonargon laser, and a X60 water immersion objective. GFP fluorescence was excited using the 488 nm laser line and collected using a standard fluorescein isothiocyanate filter set (522±32 nm). Fluorescence associated with TOPRO-3 iodide was excited using the 647 nm laser line and collected using a filter set (680±32 nm). Double fluorescence images were generated simultaneously. For Golgi complex staining, fixed cells were blocked by three washes in PBS/3% BSA. Cover slips were incubated for 1 h with Golgi p58 K antimouse antibody (Sigma, Poole, UK) at a 1:100 dilution. To detect the endoplasmic reticulum (ER), after paraformaldehyde (3% in PBS), cells were washed twice with PBS and were permeabilized with 0.5% Triton X-100 in PBS, incubated with Anti-calreticulin (Cambridge Bioscience, Cambridge, UK) for 1 h in PBS containing 3% bovine serum albumin, and washed 3 times for 5 min with PBS. Secondary antibody incubation was performed for 45 min in PBS containing 3% bovine serum albumin, after which the cells were washed as described above. Subsequently, cells were mounted in appropriate medium.
Western blot analysis
Forty-eight hours after transfection, Hela cells were harvested, and resuspended in RIPA (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 100 mM NaCl, 1% Triton X-100) buffer supplemented with protease inhibitors (Roche Diagnostics). Cell lysates were incubated on ice for 30 minutes and clarified by centrifugation at 15,000 g for 10 minutes at 4C. Total proteins were quantified using the BCA protein assay reagent (Sigma), and bovine serum albumin as the standard. 30 µg of proteins were analysed onto a SDS-PAGE according to Laëmmli and Favre (1973) . Whole cell lysates were separated on a 5% SDS-PAGE (Bio-Rad Laboratories Inc.) and transferred onto nitrocellulose membranes. The membranes were incubated with 5% non-fat dry milk in 0.1% Tween 20 in PBS at 4C overnight. Then the membranes were washed in PBS containing 0.05% Tween 20 (PBS-T).
Primary antibody was incubated for 1 h against CFTR protein (clone M3A7, Chemicon) in PBS. M3A7 is a mouse monoclonal antibody that recognizes an epitope at the C-terminal, in the region of residues 1370 to 1380. The membranes were washed with PBS-T three times and then incubated with the horseradish peroxidase-conjugated secondary antibody (Sigma) for 1 h. They were washed in PBS-T again and the blots were developed with chemiluminescence with ECL kit (Amersham Biosciences) and visualized on x-ray film after a 1-15 min exposure. Immunoblots were quantified using DuoScan transparency scanner and scion image software (developed by US NIH, http://www.scioncorp.com/).
RESULTS AND DISCUSSION
Mutations and polymorphisms in CFTR gene are responsible for cystic fibrosis disease (Qiao et al., 2008) . Genomic surveys indicate that polymorphisms affecting transcription and mRNA processing, including splicing and turnover, may account for the main share of genetic factors in human phenotypic variability. However, most of these polymorphisms remain yet to be discovered (Wang and Sadée, 2006) . Previous studies have demonstrated that polymorphisms outside the CFTR gene (Yarden et al., 2005; Yarden et al., 2004) , as well as within the gene, may affect transcription or function of the CFTR protein and modify the phenotype of some CF mutations (Huang et al., 2008) . Polymorphisms cannot cause CF by itself, but may alter CFTR protein production and/or function. There is a variation in distribution of common polymorphisms among different populations. It was thus important to compare their frequencies in patients with the frequencies in healthy population in order to assess the possible role of these polymorphisms in the monosymptomatic CF disorders. (Nikolic et al., 2006) .
Several studies have provided evidence for a possible genetic link between CFTR polymorphisms and variation in the phenotypic expression of CFTR mutations, but a number of factors that might affect the interpretation of the published results need to be clarified before reliable conclusions can be reached. This study therefore was planned to investigate the effect(s) of four common polymorphisms namely c.1540A>G, c.2694T>G, c.4404C>T and c.4521G>A alone or in allelic complexes in cis in the CFTR gene. These different constructs was established by site-directed mutagenesis as shown in Fig. (1) . In order to achieve such a purpose two different approaches were chosen and employed.
1-Subcellular localization of CFTR mutants
CFTR has been shown, by immunofluorescence analysis, to be located at the apical membrane of epithelial cells. To assess the effect of each polymorphism on membrane targeting, wild-type and mutant GFP-tagged CFTR were expressed in HeLa cells and their localizations were observed using immunofluorescence (Fig.  2) Furthermore, c.[1540A>G;2694T>G;4404C>T;4521G> A] (P7) failed to reach the cell membrane and appeared to be localized at distinct areas of the cytoplasm. The retention of these mutants in the cytoplasm was caused by aberrant protein processing in either the ER or the Golgi. A functionally low level of CFTR protein may arise due to alternative splicing of the CFTR transcript and this had detected in lung disease associated with the IVS8-5T allele of the CFTR gene (Noone et al., 2000) .
To explore the subcellular localization of CFTR mutants in more detail, co-localization studies were performed with cellular marker proteins in HeLa cells transfected by different constructs. As shown in Figure (3b-e) (Fig.  4b,c) whereas c.[1540A>G;2694T> G;4404C>T;4521G>A] is retained in the ER (Fig. 5 d) . Thus, these data revealed that mutant CFTR protein accumulates at or close to the ER or ER-derived membranes in transfected HeLa cells. These results were in agreement with the energetic point of view suggested by (Riordan et al., 1999) .
2-Processing of CFTR mutants
To study the trafficking of c.1540A>G, c.2694T>G, c.4404C>T and c.4521G>A polymorphisms in different genotypes combination expressed in HeLa cells, a western blot (wb) analysis was made. In wb experiments, a band of lower molecular mass than band B was detected by using M3A7 antibody. This band was previously shown to correspond to a polypeptide resulting from usage of an alternative translation initiation site of the CFTR mRNA. As shown in Fig. (5a) , the relative amount of fully glycosylated proteins (band C) is not different between P1, c.1540A>G; P2, c.2694T>G; P3, c.4404C>T; P4, c.4521G>A polymorphims and WT-CFTR, confirming that these mutant proteins can fold and trafficking normally to the plasma membrane in HeLa cells. However, P2, c.2694T>G and P4, c.4521G>A mutants produced significantly less band C (75.5% and 74.5% of the total CFTR, ratio C/(B+C)) than wild-type 86.5% (Fig. 5b) . These results indicated a decrease of C/(B+C) in P4, c.4521G>A polymorphism in transfected cells. This decrease (around 10% compared to the WT-CFTR) is statistically highly significant (p<0.01) when Kruskal Wallis test (http://www. viesanimales.org) was performed. The reduction in the expression level on the apical membrane of P2 and P4 CFTR may be related to its impact on splicing process. These results were in agreement with those of Steiner et al. (2010) , who implicated these polymorphisms in the etiology of several clinical symptoms in cystic fibrosis gene mutations due to its impact on splicing efficiency. 4521G>A] indicated that band density of the 150-kDa was present while that of 170-kDa was absent in all of these constructs (Fig. 5c ). This suggests that these mutated constructs are present as the immature and core-glycosylated form. The absence of glycosylation is consistent with the hypothesis that these polymorphisms are trapped in the ER and are not transferred to the Golgi apparatus where the glycosylation takes place (Riordan et al., 1999) . Therefore, these polymorphisms caused a misprocessing defect and decreased the mature CFTR form. These results are consistent with subcellular localization data as p.Phe508del-CFTR were not detectable in the plasma membrane. This postulate is also consistent with the immunofluorescence observations, which indicated that P5, P6 and P7 mutant CFTR constructs are located in ER or ER-derived membranes in transfected Hela cells (Fig. 5d) . Such alterations may be clinically insignificant in individuals without additional CFTR mutations, but may have influence on disease phenotype in patients with other relevant mutations (Davies et al., 2005) . Hence, Quantitative approaches rather than conventional genomic analysis are required to interpret the role of cSNPs (Steiner et al., 2004) . Furthermore, these polymorphisms could contribute to an increased risk in the development of chronic pancreatitis (De Cid et al., 2010) . However, these findings support the hypothesis that differences in CF phenotype could be related to the effect of the genotype on CFTR protein production and function. Further studies could help verifying these results in an attempt to characterize the possible influence of CFTR gene polymorphisms in cystic fibrosis disease. These pieces of information should be useful in understanding the pathogenesis of CF. These findings reveal that reported polymorphisms may impair the quantity and quality of CFTR protein and could contribute to CF disease development. In addition, cSNPs may be responsible for variations in the phenotypic expression of CFTR mutations. Confocal microscopy was used to determine the subcellular localization of wild-type and mutant CFTR in transfected Hela cells. F508del-CFTR was localized preferentially to the endoplasmic reticulum (ER) compartment. In contrast, mutant CFTR showed a markedly different subcellular localization pattern in the transfected cells. It did not localize to the ER. Instead, the pattern of its subcellular distribution was consistent with an aggregated form in the cytoplasm. However, the findings support the hypothesis that differences in CF phenotype could be related to the effect of the genotype on CFTR protein production and function. It is then suggested that in addition to modifier genes, SNPs may also contribute to the differences observed in the symptoms of various CF patients.
CONCLUSION
SUMMARY
To date, more than 200 sequence polymorphisms have been identified in the CFTR gene thus far and only a minority has been characterized at the cellular localization and the protein levels. In previous studies, molecular genetic analysis of the entire coding region of the CFTR gene in patients identified four common polymorphisms: c.1540A>G is located in Exon 10 of CFTR; c.2694T>G in Exon 14a, whereas c.4404C>T and c.4521G>A are located in Exon 24. The aim of this study was therefore to examine the possible effects of these polymorphisms on subcellular localization and CFTR processing in different constructs to disclose their impact on the clinical phenotype. The subcellular localization using confocal microscopy of coding single-nucleotide polymorphisms c. Cuppens (2005) . Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax, 60: 320-325.
Table (1): Sequences of site-directed mutagenesis primers. Two primers were used for each mutagenesis reaction. The altered bases, which encode the mutated amino acids are underlined and in bold shape.
Primer name Nucleotide sequence 
